Skip to main content
TipRanks
Go Ultimate75% OFF

Sarepta Therapeutics (SRPT) AI Stock Analysis

4,071 Followers
SRPT

Sarepta Therapeutics

(NASDAQ:SRPT)

Select Model
Rating:54Neutral
Price Target:$16.50▲(2.68% Upside)
Action:reiterated
Date:11/06/26

The score is driven primarily by mixed financial performance: strong multi-year revenue growth and improved leverage, but highly volatile margins/earnings and only recently improved cash generation. Technicals are a notable drag with the stock trading below major moving averages and soft momentum. Valuation provides little support due to the very high P/E and no dividend yield, partly offset by an earnings call that included raised revenue guidance and cost discipline and a corporate event that removed a key legal overhang.

Positive Factors
Commercial franchise stabilityThe PMO franchise provides a stable commercial base while ELEVIDYS demand has shown signs of stabilization. Together, these products support a sizable recurring revenue platform and give Sarepta greater operating visibility as newer gene-therapy growth develops.
Negative Factors
Declining product revenueLower product revenue, particularly from ELEVIDYS, weakens near-term growth and makes the company more dependent on PMO franchise stability. Sustained declines could reduce resources available for pipeline investment and delay the operating leverage expected from gene-therapy expansion.

Sarepta Therapeutics Key Performance Indicators (KPIs)

Revenue by SegmentSplits revenue across business lines and markets — for example commercial product sales, collaboration or licensing income, and geographic regions — to reveal where growth is coming from and how diversified the business is. Helps investors see whether Sarepta depends mainly on commercial sales from a small set of drugs, benefits from partner deals or milestone payments, and how exposure to different markets or revenue types affects risk and upside.

$0.00$200.00M$400.00M$600.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Products revenue showed a big build into 2024 and then trended down into early‑2026, reflecting uneven Alevitus commercialization and timing-driven one‑time therapy dynamics; Collaboration & Other is extremely lumpy and Q1‑2026 contains a large non‑cash Roche item that materially inflates headline revenue. Management’s reiterated guidance and strong gross margins support financial stability, but underlying product momentum is gradual and dependent on demand recovery and small safety cohorts—so focus on product revenue trajectory and upcoming clinical/regulatory readouts, not the headline collaboration spikes.

Data provided by:The Fly

Sarepta Therapeutics (SRPT) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%SRPT-7.86%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.72B
Dividend Yield
―
Average Volume (3M)
2.74M
Price to Earnings (P/E)
178.6
Beta (1Y)
1.37
Revenue Growth
-18.95%
EPS Growth
59.85%
Country
US
Employees
835
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Sarepta Therapeutics Business Overview & Revenue Model

Company Description

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company...

How the Company Makes Money

Sarepta primarily makes money by selling its commercial DMD therapies, generating product revenue from U.S. and other applicable market sales of EXONDYS 51, VYONDYS 53, AMONDYS 45 (exon-skipping therapies), and ELEVIDYS (a gene therapy). Revenue is d...

Sarepta Therapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-8.54%|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call conveyed focused optimism, supported by stabilized ELEVIDYS demand, strong PMO performance, raised revenue guidance, positive pipeline data, upcoming DM1 and FSHD readouts, non-GAAP profitability, and nearly $1 billion of cash and investments. These positives were partially offset by year-over-year revenue declines driven by lower ELEVIDYS sales, significant take-or-pay charges and related gross-margin pressure, a third-quarter GAAP operating loss, the termination of ENVISION enrollment, and continued uncertainty around near-term ELEVIDYS growth and the non-ambulatory label.

Positive Updates

Raised 2026 Revenue Guidance
Based on strong PMO performance and stabilization in ELEVIDYS, Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion.

Negative Updates

Decline in Product Revenue
Third-quarter total product revenues were $324 million, a decrease of 13% year-over-year, while first-nine-month product revenues were $983 million, a decrease of 34%. The year-over-year declines were driven by lower ELEVIDYS sales.

Company Guidance

Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion; ELEVIDYS revenue was $83 million in the third quarter and is expected in the fourth quarter to trend in line with Q3, while the PMO franchise is expected to remain strong. Full-year combined non-GAAP R&D and SG&A expense guidance was narrowed to between $800 million and $825 million. The company expects to submit an sBLA for the under-four population mid-next year, complete enrollment of ENDEAVOR Cohort eight by the end of this year and engage with FDA in Q1 2027, share DM1 and FSHD MAD data in the coming weeks, receive higher-dose data early next year, and generate Huntington’s disease proof-of-biology data sometime around mid-year next year.

Sarepta Therapeutics Financial Statement Overview

Summary

Revenue scaled materially over the long run, but profitability and margins have been highly volatile (notably the 2025 loss) and only near break-even in the latest TTM. Leverage has improved and the latest TTM shows positive operating and free cash flow, but the cash-flow history is inconsistent, making durability the key risk.

Income Statement

54Neutral

Balance Sheet

61Positive

Cash Flow

57Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.96B2.20B1.90B1.24B933.01M701.89M
Gross Profit1.10B1.32B1.58B1.09B793.02M604.84M
EBITDA155.20M-647.97M316.89M-453.69M-594.85M-317.41M
Net Income14.76M-713.41M235.24M-535.98M-703.49M-418.78M
Balance Sheet
Total Assets3.17B3.35B3.96B3.26B3.13B3.15B
Cash, Cash Equivalents and Short-Term Investments878.78M939.65M1.35B1.68B1.99B2.12B
Total Debt1.05B1.04B1.34B1.40B1.62B1.15B
Total Liabilities1.64B2.21B2.44B2.41B2.74B2.22B
Stockholders Equity1.53B1.14B1.53B859.34M384.95M928.01M
Cash Flow
Free Cash Flow-31.60M-307.45M-352.74M-588.34M-357.60M-481.66M
Operating Cash Flow-17.12M-205.48M-205.79M-500.99M-325.35M-443.17M
Investing Cash Flow-424.30M69.64M755.56M-165.80M-1.05B495.41M
Financing Cash Flow-38.73M-168.34M124.81M125.00M232.51M561.57M

Sarepta Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price16.07

Price Trends

50DMA18.59Negative
100DMA18.33Negative
200DMA18.52Negative

Market Momentum

MACD-0.53Positive
RSI37.34Neutral
STOCH9.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRPT, the sentiment is Negative. The current price of 16.07 is below the 20-day moving average (MA) of 17.95, below the 50-day MA of 18.59, and below the 200-day MA of 18.52, indicating a bearish trend. The MACD of -0.53 indicates Positive momentum. The RSI at 37.34 is Neutral, neither overbought nor oversold. The STOCH value of 9.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRPT.

Sarepta Therapeutics Risk Analysis

Sarepta Therapeutics disclosed 66 risk factors in its most recent earnings report. Sarepta Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Deviations from manufacturing, testing, packaging and distribution processes and procedures could result in manufacturing delays or delays in product release, which may harm our business.Q2, 2026
2.If we fail to maintain effective internal controls, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.Q4, 2025
3.Our announced strategic restructuring plan may not result in anticipated reductions in our annual combined research and development and selling, general and administrative expenses and may disrupt our business in unexpected ways.Q4, 2025

Sarepta Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SRPT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SRPTSRPT54Neutral$1.72B178.561.04%―-18.95%59.85%
TSHATSHA54Neutral$1.34B-9.53-51.87%―-13.07%-23.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
QUREQURE50Neutral$1.67B-6.72-96.34%―28.04%19.12%
RARERARE48Neutral$1.64B-3.10213.22%―15.76%12.63%
WVEWVE45Neutral$617.33M-2.92-44.48%―-35.07%-45.17%
SLDBSLDB42Neutral$763.42M-3.82-67.78%――28.59%

* Healthcare Sector Average

Performance Comparison

0%100%SRPTRAREQUREWVESLDBTSHADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SRPT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SRPTSarepta Therapeutics Inc.16.07-1.47-8.38%
RAREUltragenyx Pharmaceutical, Inc.16.08-16.46-50.58%
QUREuniQure N.V.23.81-6.52-21.50%
WVEWave Life Sciences Pte. Ltd3.13-4.02-56.22%
SLDBSolid Biosciences6.842.5057.60%
TSHATaysha Gene Therapies, Inc.4.10-0.02-0.49%

Sarepta Therapeutics Corporate Events

Business Operations and StrategyLegal Proceedings

Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute

Positive
Sep 23, 2026

On September 23, 2026, Sarepta Therapeutics, its affiliate Sarepta Therapeutics Three, REGENXBIO, the Trustees of the University of Pennsylvania and Catalent entered into a settlement resolving patent infringement litigation and related appeals invol...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026